(GP 11) The views on different aspects of primary prevention varied, despite the fact that all the GPs in our study worked in the same county and were recommended to use the same guidelines which theoretically could have restricted the variation.
The parameters K1, K2, I1, and I2 can be optimized empirically as in the case of OSD(I1,I2 to fine-tune the BER performance versus the implementation complexity; it is recommended to use the same parameters as for the OSD(I1,I2 decoding.
It is recommended to use the same id as the name for ease of use.
It is recommended to use the same dosages and dosage forms that the patient used before the trial, to start the trial with a run-in period, to formulate both general and individualised decision rules regarding the efficacy of treatment, to adjust treatment policies immediately after the trial, and to provide adequate instructions and support if treatment is adjusted.
Due to heterogeneity within the tumor microenvironment both within different regions of the same tumor (intra-tumoral) and across different tumors within one or more animals (inter-tumoral), it is recommended to maintain the same microenvironment structures (e.g., microvasculature, tissue, and cells) within the microscope field of view for the duration of the experiment.
Therefore, it is strongly recommended to use the same mode of administration when comparing groups or changes over time.
Recommended discounting rates range from 1.5% - 5% for effects and 3% - 5% for costs whereby it is mostly recommended to use the same rate for costs and effects.
When adding property and linker tables, it is recommended to follow the same naming style and fields used for other linker and property tables in Chado.
In most screening programs, women with nonproliferative disease or with proliferative disease without atypia are recommended to follow the same screening strategy as women with negative mammograms (which is to continue screening).
Currently, for TN tumours it is recommended to use the same chemotherapy regimen as for non-TN disease, mostly a 3-week regimen of an anthracyclin cyclophophamide combination followed by docetaxel.
